This template was built with Webflow's free Prospero UI Kit. Learn more
Focused on Advancing Strategic Research
Our Mission:

The SCN2A Foundation is a global initiative dedicated towards accelerating research and treatment for SCN2A. We plan to achieve this by building collaborative networks among the global research community, organizing resources, and strategically investing in highly focused research directed towards therapeutic development.

To Accomplish our Goals - we’ll focus on 4 areas:
Community Development

Growing and engaging a global collaborative community to support the most up to date information about SCN2A related therapies

Awareness & Fundraising

Create and promote patient led events to raise awareness for funding SCN2A targeted therapeutic research


Fund, develop, execute, and iterate on targeted research to support therapeutic development for SCN2A.

Strengthen Collaboration

We plan to unite the global communities of SCN2A related physicians, researchers, patients, and industry through annual meetings, online forums, and synergistic partnerships - with an open source philosophy.

Our Story

Our story began when we nearly lost our son due to a change in epileptic medication to treat his epilepsy. Diagnosed autistic at 14 months, then later having a series of catastrophic seizures at 18 months, our son Jack was placed on a broad spectrum epilepsy medicine that caused a series harsh side effects.

After a year without seizures, we asked for and were given what everyone felt would be a medication with a better side effect profile. Unfortunately, this change resulted in life threatening seizures, and after months of hospital visits, our son formally received genetic testing, and his SCN2A diagnosis.

After receiving life saving guidance from a mom in the SCN2A community, we came to understand that Jack’s particular variant of SCN2A should not taken sodium channel blockers.

Had our son received genetic testing after his first seizure, and had there been publicly available information on this, we would have years of development back with our son.

After finishing course work in drug development, and with the scientific & clinical guidance of prominent functional medicine experts, precision health consultants, and geneticists, the SCN2A Foundation was co-founded by Shannon and Jason Curry.

Our goal is to accelerate targeted research that’s specific to therapeutic development for SCN2A, and to improve survival and its debilitating symptoms.

“We've found and prioritized strategic projects to improve diagnosis and treatment for SCN2A, and are quickly and methodically moving forward after them.

But we can’t do this alone.”
Jason Curry, Co-Founder & Director
Our Team & Partners
Board Member
Board Member
Board Member
Co - Founder
Shannon Curry RN
Co - Founder
Partners & Advisors
Scientific Advisory MD, PhD, FACMG
Strategic Advisor MD, PHD, MBA
Medical Advisor MS, CN
Medical Advisor MD
Director of the Hugh Kaul Precision Medicine Institute
PhD, CEO Perlara
PhD - Strategic Advisor

Help us Cure SCN2A